Loxo Oncology Inc. | Ownership
Companies that own Loxo Oncology Inc.
The Vanguard Group, Inc.
2,333,177
7.66%
264,693
0.01%
06/30/2018
T. Rowe Price Associates, Inc.
2,193,525
7.2%
224,442
0.05%
06/30/2018
Sands Capital Management LLC
2,008,237
6.59%
-121,236
0.87%
06/30/2018
BlackRock Fund Advisors
1,888,739
6.2%
221,851
0.02%
06/30/2018
Wellington Management Co. LLP
1,823,983
5.99%
-141,953
0.06%
06/30/2018
Fidelity Management & Research Co.
1,610,037
5.28%
-1,099,651
0.03%
06/30/2018
Fidelity (Canada) Asset Management ULC
1,148,696
3.77%
646,138
0.28%
06/30/2018
OppenheimerFunds, Inc.
1,115,675
3.66%
66,794
0.11%
06/30/2018
SSgA Funds Management, Inc.
877,166
2.88%
-138,567
0.01%
06/30/2018
FIAM LLC
690,665
2.27%
-376,556
0.23%
06/30/2018
| Address |
281 Tresser Boulevard
Stamford Connecticut 06901
United States
|
|
Employees
|
- |
| Website |
http://www.loxooncology.com |
| Updated |
09/14/2018 |
| Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. |
